Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film
July 27, 2023 07:00 ET
|
Aquestive Therapeutics, Inc.
Reports positive topline data from latest pilot pharmacokinetic (PK) studyPlans to submit pivotal PK clinical study protocol to the FDA in early AugustAnticipates commencement of its definitive...
Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET
July 25, 2023 16:01 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...
Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference
July 25, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit
July 06, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment
June 29, 2023 08:42 ET
|
Aquestive Therapeutics, Inc.
Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of ageAppointed Carl N. Kraus, M.D. as Chief Medical Officer WARREN, N.J.,...
Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study
May 31, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
Time to maximum blood concentration (median Tmax) for Anaphylm was 10 minutes with a range of 5 to 20 minutesEarly drug exposure at 10 minutes (partial area under the curve, or pAUC0-10min) for...
Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 02, 2023 16:31 ET
|
Aquestive Therapeutics, Inc.
Continues to advance development of AQST-109 (epinephrine sublingual film); received FDA conditional approval of brand name Anaphylm™Raises full year 2023 revenue and non-GAAP adjusted EBITDA...
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
April 26, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care...
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
April 20, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...
Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET
April 18, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., April 18, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...